Close Menu

tumor mutational burden

Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.

A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.

With TMB as a CDx, the drug will be available to more patients as a salvage option, but doctors will still need to consider the complex biomarker amid evolving research.

The study suggests that pediatric low-grade gliomas driven by genetic rearrangements tend to be diagnosed earlier and have better outcomes than those driven by SNVs.

An integrated analysis involving prostate cancer patients from China highlighted frequent FOXA1 mutations and deletions in two other genes.

The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.

Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.

Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.

In addition to developing standards for proteomics, metabolomics, and other kinds of data, DNAnexus will develop tools to help reviewers quickly and easily assess analysis pipelines.

The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing. 

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.